Editorial Office, Journal of Nursing Research and Practice, Windsor, Berkshire, United Kingdom

Publications

• Opinion   
  Why, when, and how should recipients of the covid-19 vaccine be tested for anti-sars-cov-2 antibodies?
  Author(s): Stephen Paul*
  
  Coronavirus disease 2019 covid-19 hospitalizations and deaths can be prevented in large part by universal vaccination, although there is significant inter-individual variability in the effectiveness of the covid-19 vaccinations, mostly because of recipients' variable immunological responses. As a result, the objective of this opinion piece is to explore several elements of the possibility of monitoring anti-sars-cov-2 antibodies both before and after covid-19 vaccination, highlighting the benefits and drawbacks of this approach. In conclusion, the benefits of testing anti-sars-cov-2 antibodies in people who have received the covid-19 vaccination include determining the baseline seroprevalence of sars-cov-2 infection in people who have not received the vaccine, early detection of low or non-responders to the covid-19 vaccination, and Timely Detection of faster anti-sars-cov-2 antib.. Read More»
  DOI: DOI:10.37532 Puljnrp .22.6(10).166-168.

  • Abstract
  • Full-Text
  • PDF